Group Leader: Manuel Guzmán


Our research focuses globally on the study of the mechanisms underlying the control of neural cell generation and survival by the endocannabinoid system, especially in the corticostriatal circuit. On the one hand, we aim at deciphering the molecular and cellular basis of endocannabinoid system-mediated neuroprotection, by studying (i) signal transduction pathways, (ii) new interactors of cannabinoid receptors, and (iii) the differential role of specific subpopulations of cannabinoid receptors. On the other hand, in the pathological context, we are evaluating (i) the neuroprotective activity of the endocannabinoid system in animal models of Huntington’s disease (HD), (ii) the possible pathogenic role of cannabinoid CB1 receptor in HD, and (iii) the participation of the glial endocannabinoid system in the neurodegenerative processes associated to HD. We intend to define the potential therapeutic relevance of these processes.

Our research on neuroprotection and Huntington’s disease is mainly funded by MINECO (Biomedicine/SAF Program) and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED). For further information click here.

For further information on Huntington’s disease-related research you can visit the following web sites:

CHDI Foundation

European Huntington’s Disease Network

International Huntington Association